News and Trends 16 Feb 2017 The Patent Office has Spoken: What does it Mean for CRISPR in Europe? The US Patent Office has ruled that the Broad Institute’s CRISPR patents do not interfere with those from UC Berkeley. While this might sound like everybody wins, it’s actually a loss for Charpentier and the CRISPR Therapeutics team. CRISPR has been hailed as the ‘scientific discovery of the century’. This molecular technique could be used […] February 16, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2017 Actelion’s key Drug linked to Deaths, prompting EMA Investigation Johnson & Johnson is certainly counting on its recent acquisition of the European biotech success Actelion to upgrade its top line. Now Actelion’s key product, Uptravi, may be facing some safety issues. One of Actelion’s new products, Uptravi, was launched last January against pulmonary arterial hypertension (PAH) and – with a €150000 ($160,000) price tag – it makes up a […] February 15, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2017 French Biotech bids for Crowdfunding in Neurodegenerative Disease AlzProtect is aiming to raise €1M via equity crowdfunding to fund a Phase Ib trial in progressive supranuclear palsy (PSP). AlzProtect is a biotech in Lille, France, fighting neurodegenerative disease. To support the progression of its lead candidate, AZP2006, the company has decided to turn to an unusual source of money that seems to be […] February 15, 2017 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2017 French Biotech gets a Boost in the NASH Race with a Successful IPO Inventiva has completed an IPO on Euronext Paris raising €48M that will support the advancement of its pipeline, which includes big indications such as NASH. Inventiva, a drug discovery company from France, is the protagonist today of a successful biotech IPO on Euronext Paris despite the financial difficulties of past years. The company has raised €48M, which will […] February 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2017 Optogenetics: What Makes It a Powerful Neuroscience Tool? It’s a brand-new field and possibilities seem infinite. Here’s what you need to know about its rapid development into a powerful genetic tool. What is Optogenetics? What if you could activate and deactivate neurons by simply switching on the lights? That’s the basis of optogenetics, the control of cell behavior via light-sensitive proteins. Optogenetics is a […] February 15, 2017 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2017 Suffering from House Dust Mite Allergy? A New Therapy is on its Way Allergy Therapeutics, a UK-based biotech company, just announced the approval of its clinical trial application in Spain to advance its next-generation house dust mite allergy vaccine into phase I clinical development. The company Allergy Therapeutics is developing immunotherapeutic vaccines for the treatment of allergies and has been quite successful. Their Pollinex Quattro range of vaccines against […] February 14, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2017 Which European Country is Winning the Race in Clinical Development? A report from the French Association of Biotechnology, France Biotech, could be alerting the French health-care sector this week. The report lists the top European countries leading in clinical development – with France clearly dragging behind other Western European countries. Based on data from the EU Clinical Trials Register, the data compiled by France Biotech reveals which countries are on […] February 14, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2017 Dual HIV Therapy: GSK and Gilead Battle over Whose Drug is the Best GSK announced Phase III results for dolutegravir, which could reduce triple HIV therapy down to two drugs, but Gilead is trying to prove that its candidate bictegravir is better. GSK and Gilead have announced they will present detailed data backing their candidates for a dual HIV therapy. The battlefield will be the Annual Conference on Retroviruses […] February 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 14 Feb 2017 10 European Scientists who are the Best at Co-founding Biotech Companies The “Eureka” moment in the lab is far from the end of a successful story. Whether it’s the recipe for the next wonder therapy or a means of independence from fossil fuels, creating a company and making scientific discoveries to commercial reality is hard. We take a look at the best at translating research from the bench […] February 14, 2017 - 6 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 13 Feb 2017 Biotech from the Bermuda Islands Brings Good News for Dementia Patients Axovant Sciences has announced positive preliminary results from a Phase II trial directed at reducing hallucinations in patients with dementia. Axovant Sciences is a biotech located in Bermuda, a British tropical island in the Atlantic ocean. From there, the company develops drugs against dementia. The company was founded by young biotech entrepreneur Vivek Ramaswamy, which has […] February 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 13 Feb 2017 To the Rescue: A Final Phase III Success for Post-Operative Nausea The dopamine antagonist Baremsis is on its way to FDA approval for the treatment and prophylaxis of post-operative nausea & vomiting, after succeeding in a final phase III study. Acacia Pharma, one of our Cambridge top 15 biotechs, is repurposing marketed drugs to provide supportive treatments for post-surgical or cancer patients. Their lead project, Baremsis, is a dopamine antagonist, which Acacia is […] February 13, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Infographics 13 Feb 2017 Infographic: What’s in Europe’s Immuno-oncology Pipeline? While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for its potential to cure cancer. What new therapies are European biotech cooking up? Since the dawn of immuno-oncology broke with checkpoint inhibitors, innovative therapies like Keytruda and Rituxan from big pharma have taken the world by storm. European biotech’s pipeline is […] February 13, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email